Abbott Laboratories (ABT) Stock

$130.61 -1.18 (-0.90%)
Market Cap: $226.54B | NYSE

Abbott Laboratories Chart


Company Profile

Price: $130.61

Market Cap: $226.54B

Exchange: NYSE

CEO: Mr. Robert B. Ford

Sector: Healthcare

Industry: Medical - Devices

Employees: 114.00K

Headquarters: North Chicago, IL

Business Summary

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories News

AHCO or ABT: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Products sector might want to consider either AdaptHealth Corp. (AHCO) or Abbott (ABT). But which of these two stocks is more attractive to value investors?

News image

Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.

DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

News image

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.

Most companies don't survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull it off.

News image

ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?

Abbott projects organic sales growth between 7.5% and 8.5% for 2025.

News image

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

News image

3 No-Brainer Healthcare Stocks to Buy With $200 Right Now

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.

News image

Why We Chose Abbott Labs Stock Amid Tariff And DeepSeek Volatility

The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week.

News image

Here are the best performing dividend aristocrats stocks in 2025

Dividend aristocrat stocks have largely done well in the past few years. The closely-followed ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has jumped by over 133% from its lowest level in 2020.

News image

Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care

New survey shows 40% of people living with diabetes have skipped or missed a doctor's appointment due to shame or stigma1 70% of people with diabetes said supportive comments from others can significantly boost their motivation to manage their condition1 Abbott launches film that highlights challenges of living life with diabetes ABBOTT PARK, Ill., Feb. 4, 2025 /PRNewswire/ -- 'One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have diabetes.

News image

2 Unstoppable Dividend Stocks That Will Pay You for Life

In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As most income seekers want to avoid this fate, they might consider turning to arguably the most elite group of dividend payers on the market: Dividend Kings.

News image

My Best Dividend Aristocrats For February 2025

The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 42 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.

News image

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

News image

Reasons to Retain ABT Stock in Your Portfolio Now

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

News image

Expanding EPD Business Supports ABT Stock Amid Macro Issues

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

News image

Is There More Upside For ABT Stock After A 10% Jump In A Week?

Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and $1.34, respectively.

News image

Abbott Laboratories: Strong Q4 Results And Bullish Outlook

On January 22, Abbott Laboratories published financial results for the fourth quarter of 2024, initially receiving mixed reactions from Wall Street. However, its revenue was about $10.97 billion for the three months ended December 31, 2024, up 7.2% year-on-year, driven by strong sales in the company's Medical Devices segment. Moreover, Abbott expects its revenue to grow by 7.5% to 8.5% in 2025, while its adjusted diluted EPS will be between $5.05 and $5.25, implying double-digit percentage growth year-over-year.

News image

Abbott Laboratories Will Outperform Healthcare Stocks in 2025

The outlook and technical action suggest Abbott Laboratories NYSE: ABT will lead healthcare names like Johnson & Johnson NYSE: JNJ higher in 2025. While each produced a solid quarter, Abbott Laboratories outperformed and has a more robust outlook.

News image

What Can The Dividend Kings Deliver In 2025?

The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by earnings growth and dividends, with the change in P/E ratio being a detractor. I breakdown the components of total return for each Dividend King by sector to gain insights into current valuation.

News image

Why Is Abbott Stock Trading Higher On Thursday?

On Wednesday, Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.

News image

Two Contrarian Dividends With Triple-Digit Potential For Trump 2.0

Tariff Day has left us with Canada and Mexico in the crosshairs. With North American trade in focus, this may actually give a respite to stocks with supply chains elsewhere and light a fire under them.

News image

Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)

Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month. The company looks set up to deliver double-digit annual adjusted diluted EPS growth for the foreseeable future. Abbott Laboratories enjoys an AA- credit rating from S&P on a stable outlook.

News image

My Top 5 Stocks to Buy in Early 2025

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game-changing technologies to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors.

News image

Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Wednesday.

News image

Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript

Abbott Laboratories (NYSE:ABT ) Q4 2024 Earnings Conference Call January 22, 2025 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman & Chief Executive Officer Phil Boudreau - Executive Vice President, Finance & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Travis Steed - BofA Securities Vijay Kumar - Evercore ISI Josh Jennings - TD Cowen David Roman - Goldman Sachs Joanne Wuensch - Citi Danielle Antalffy - UBS Matt Miksic - Barclays Operator Good morning and thank you for standing by. Welcome to Abbott's Fourth Quarter 2024 Earnings Conference Call.

News image

Compared to Estimates, Abbott (ABT) Q4 Earnings: A Look at Key Metrics

The headline numbers for Abbott (ABT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News image

Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall

On Wednesday, Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.

News image

Abbott (ABT) Q4 Earnings Meet Estimates

Abbott (ABT) came out with quarterly earnings of $1.34 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.19 per share a year ago.

News image

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates

Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.

News image

Abbott forecasts in line annual profit on medical device sales

Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including glucose-monitoring products.

News image

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook

Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1 Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent2 Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5% ABBOTT PARK, Ill., Jan. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2024.

News image

Abbott Laboratories Earnings

This section highlights Abbott Laboratories's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 16, 2025
Time: Before Market
Est. EPS: $1.07
Status: Unconfirmed

Last Earnings Results

Date: January 22, 2025
EPS: $1.34
Est. EPS: $1.34
Revenue: $10.97B

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-01-22 $1.34 $1.34
Read Transcript Q3 2024 2024-10-16 $1.20 $1.21
Read Transcript Q2 2024 2024-07-18 $1.10 $1.14
Read Transcript Q1 2024 2024-04-17 $0.95 $0.98
Read Transcript Q4 2023 2024-01-23 N/A N/A
Read Transcript Q3 2023 2023-10-17 N/A N/A
Read Transcript Q2 2023 2023-07-19 N/A N/A
Read Transcript Q1 2023 2023-04-18 N/A N/A

Financial Statements

Access annual & quarterly financial statements for Abbott Laboratories, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Revenue $40.11B $43.65B $43.08B $34.61B $31.90B
Cost of Revenue $17.98B $19.14B $18.54B $15.00B $13.23B
Gross Profit $22.13B $24.51B $24.54B $19.61B $18.67B
Gross Profit Ratio 55.18% 56.15% 56.97% 56.65% 58.53%
Research and Development Expenses $2.74B $2.89B $2.74B $2.42B $2.44B
General and Administrative Expenses $- $- $- $- $-
Selling and Marketing Expenses $- $- $- $- $-
Selling General and Administrative Expenses $10.95B $11.25B $11.32B $9.70B $9.77B
Other Expenses $1.97B $2.01B $2.05B $2.13B $1.94B
Operating Expenses $15.66B $16.15B $16.11B $14.25B $14.14B
Cost and Expenses $33.63B $35.29B $34.65B $29.25B $27.37B
Interest Income $385.00M $183.00M $43.00M $46.00M $94.00M
Interest Expense $637.00M $375.00M $490.00M $500.00M $576.00M
Depreciation and Amortization $3.24B $3.27B $3.54B $3.33B $3.01B
EBITDA $10.61B $12.38B $12.74B $8.79B $7.77B
EBITDA Ratio 26.44% 24.50% 24.95% 21.94% 20.87%
Operating Income $6.48B $8.36B $8.43B $5.36B $4.53B
Operating Income Ratio 16.15% 19.16% 19.56% 15.48% 14.21%
Total Other Income Expenses Net $186.00M $-56.00M $-214.00M $-389.00M $-455.00M
Income Before Tax $6.66B $8.31B $8.21B $4.97B $4.08B
Income Before Tax Ratio 16.61% 19.03% 19.06% 14.36% 12.78%
Income Tax Expense $941.00M $1.37B $1.14B $497.00M $390.00M
Net Income $5.72B $6.93B $7.07B $4.50B $3.69B
Net Income Ratio 14.27% 15.88% 16.42% 12.99% 11.56%
EPS $3.30 $3.94 $3.97 $2.52 $2.07
EPS Diluted $3.27 $3.91 $3.94 $2.50 $2.06
Weighted Average Shares Outstanding 1.73B 1.75B 1.77B 1.77B 1.77B
Weighted Average Shares Outstanding Diluted 1.75B 1.76B 1.79B 1.79B 1.78B
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Revenue $10.63B $10.38B $9.96B $10.24B $10.14B $9.98B $9.75B $10.09B $10.41B $11.26B $11.89B $11.47B $10.93B $10.22B $10.46B $10.70B $8.85B $7.33B $7.73B $8.31B
Cost of Revenue $4.70B $4.57B $4.42B $4.98B $4.61B $4.48B $4.31B $4.59B $4.63B $4.93B $4.99B $4.77B $4.42B $4.95B $4.40B $4.49B $3.97B $3.26B $3.28B $3.43B
Gross Profit $5.94B $5.81B $5.54B $5.26B $5.54B $5.50B $5.43B $5.50B $5.78B $6.32B $6.91B $6.70B $6.50B $5.28B $6.05B $6.21B $4.89B $4.07B $4.45B $4.88B
Gross Profit Ratio 55.83% 55.96% 55.64% 51.34% 54.60% 55.07% 55.74% 54.48% 55.53% 56.18% 58.07% 58.44% 59.53% 51.61% 57.91% 58.01% 55.20% 55.47% 57.53% 58.70%
Research and Development Expenses $713.00M $698.00M $679.00M $690.00M $672.00M $715.00M $654.00M $725.00M $782.00M $684.00M $697.00M $762.00M $672.00M $654.00M $654.00M $698.00M $580.00M $564.00M $578.00M $595.00M
General and Administrative Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $2.55B $- $- $2.55B $2.41B
Selling and Marketing Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $22.00M $- $- $- $-
Selling General and Administrative Expenses $2.90B $2.92B $2.94B $2.70B $2.60B $2.62B $2.62B $2.97B $2.73B $2.76B $2.79B $3.05B $2.77B $2.73B $2.78B $2.57B $2.30B $2.28B $2.55B $2.41B
Other Expenses $470.00M $-471.00M $-472.00M $109.00M $83.00M $498.00M $491.00M $496.00M $498.00M $82.00M $512.00M $63.00M $74.00M $79.00M $61.00M $78.00M $46.00M $-22.00M $1.00M $51.00M
Operating Expenses $4.08B $4.08B $4.09B $3.39B $3.80B $3.80B $3.82B $4.19B $4.01B $3.95B $4.00B $4.32B $3.96B $3.88B $3.95B $3.78B $3.39B $3.39B $3.69B $3.49B
Cost and Expenses $8.78B $8.65B $8.51B $8.38B $8.40B $8.28B $8.13B $8.79B $8.64B $8.88B $8.98B $9.09B $8.38B $8.83B $8.35B $8.27B $7.36B $6.66B $6.97B $6.92B
Interest Income $91.00M $82.00M $80.00M $89.00M $69.00M $61.00M $52.00M $88.00M $55.00M $26.00M $14.00M $11.00M $10.00M $11.00M $11.00M $9.00M $10.00M $9.00M $18.00M $25.00M
Interest Expense $142.00M $58.00M $61.00M $235.00M $166.00M $159.00M $153.00M $154.00M $86.00M $132.00M $117.00M $120.00M $123.00M $123.00M $124.00M $127.00M $127.00M $125.00M $121.00M $139.00M
Depreciation and Amortization $801.00M $805.00M $805.00M $813.00M $824.00M $800.00M $806.00M $807.00M $815.00M $822.00M $823.00M $883.00M $847.00M $874.00M $934.00M $866.00M $808.00M $825.00M $828.00M $756.00M
EBITDA $2.91B $2.64B $2.34B $2.87B $2.59B $2.48B $2.44B $2.28B $2.69B $3.30B $3.83B $3.84B $3.46B $2.83B $3.11B $3.55B $2.25B $1.55B $1.63B $2.27B
EBITDA Ratio 27.33% 16.60% 14.55% 26.14% 25.56% 24.68% 25.48% 22.60% 22.68% 29.37% 29.44% 25.77% 28.73% 19.32% 25.62% 28.20% 23.17% 16.42% 17.09% 23.13%
Operating Income $1.86B $1.72B $1.45B $1.86B $1.77B $1.66B $1.68B $1.30B $1.77B $2.38B $2.91B $2.38B $2.55B $1.39B $2.11B $2.43B $1.50B $672.00M $758.00M $1.39B
Operating Income Ratio 17.48% 16.60% 14.55% 18.20% 17.44% 16.67% 17.22% 12.92% 17.00% 21.11% 24.48% 20.74% 23.30% 13.62% 20.17% 22.73% 16.89% 9.17% 9.81% 16.71%
Total Other Income Expenses Net $81.00M $-62.00M $50.00M $427.00M $24.00M $94.00M $53.00M $16.00M $-12.00M $-24.00M $-36.00M $-51.00M $-53.00M $-44.00M $-66.00M $-44.00M $-74.00M $-146.00M $-125.00M $-149.00M
Income Before Tax $1.94B $1.61B $1.44B $1.79B $1.67B $1.64B $1.56B $1.32B $1.76B $2.35B $2.88B $2.33B $2.49B $1.35B $2.04B $2.39B $1.42B $526.00M $633.00M $1.24B
Income Before Tax Ratio 18.24% 15.49% 14.41% 17.53% 16.47% 16.40% 16.03% 13.08% 16.89% 20.89% 24.18% 20.29% 22.81% 13.19% 19.54% 22.32% 16.05% 7.18% 8.19% 14.91%
Income Tax Expense $294.00M $305.00M $211.00M $201.00M $235.00M $261.00M $244.00M $287.00M $323.00M $334.00M $429.00M $338.00M $393.00M $159.00M $250.00M $230.00M $189.00M $-11.00M $89.00M $191.00M
Net Income $1.65B $1.30B $1.23B $1.59B $1.44B $1.38B $1.32B $1.03B $1.44B $2.02B $2.45B $1.99B $2.10B $1.19B $1.79B $2.16B $1.23B $537.00M $564.00M $1.05B
Net Income Ratio 15.48% 12.55% 12.29% 15.56% 14.16% 13.78% 13.52% 10.24% 13.78% 17.93% 20.57% 17.34% 19.22% 11.63% 17.15% 20.20% 13.92% 7.33% 7.30% 12.62%
EPS $0.95 $0.75 $0.71 $0.92 $0.83 $0.79 $0.76 $0.59 $0.82 $1.15 $1.40 $1.13 $1.19 $0.67 $1.01 $1.22 $0.70 $0.30 $0.32 $0.60
EPS Diluted $0.94 $0.74 $0.70 $0.91 $0.82 $0.78 $0.75 $0.59 $0.81 $1.14 $1.38 $1.12 $1.17 $0.66 $1.00 $1.21 $0.69 $0.30 $0.32 $0.59
Weighted Average Shares Outstanding 1.73B 1.73B 1.73B 1.73B 1.74B 1.74B 1.74B 1.74B 1.74B 1.75B 1.75B 1.76B 1.77B 1.77B 1.78B 1.77B 1.77B 1.77B 1.77B 1.76B
Weighted Average Shares Outstanding Diluted 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.76B 1.76B 1.77B 1.78B 1.79B 1.79B 1.79B 1.79B 1.79B 1.78B 1.78B 1.78B
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Cash and Cash Equivalents $6.90B $9.88B $9.80B $6.84B $3.86B
Short Term Investments $383.00M $288.00M $450.00M $310.00M $280.00M
Cash and Short Term Investments $7.28B $10.17B $10.25B $7.15B $4.14B
Net Receivables $6.57B $6.22B $6.49B $6.41B $5.42B
Inventory $6.57B $6.17B $5.16B $5.01B $4.32B
Other Current Assets $2.26B $2.66B $2.35B $1.87B $1.79B
Total Current Assets $22.67B $25.22B $24.24B $20.44B $15.67B
Property Plant Equipment Net $11.28B $9.16B $8.96B $9.03B $8.04B
Goodwill $23.68B $22.80B $23.23B $23.74B $23.20B
Intangible Assets $8.81B $10.45B $12.74B $14.78B $17.02B
Goodwill and Intangible Assets $32.49B $33.25B $35.97B $38.53B $40.22B
Long Term Investments $799.00M $766.00M $816.00M $821.00M $883.00M
Tax Assets $- $6.03B $5.21B $3.73B $3.08B
Other Non-Current Assets $5.97B $- $- $- $-
Total Non-Current Assets $50.54B $49.21B $50.96B $52.11B $52.22B
Other Assets $- $- $- $- $-
Total Assets $73.21B $74.44B $75.20B $72.55B $67.89B
Account Payables $4.29B $4.61B $4.41B $3.95B $3.25B
Short Term Debt $1.32B $2.48B $999.00M $461.00M $1.68B
Tax Payables $492.00M $343.00M $306.00M $362.00M $226.00M
Deferred Revenue $174.00M $- $- $- $-
Other Current Liabilities $7.55B $8.06B $7.39B $7.14B $5.70B
Total Current Liabilities $13.84B $15.49B $13.11B $11.91B $10.86B
Long Term Debt $14.55B $15.46B $18.25B $19.43B $17.42B
Deferred Revenue Non-Current $- $- $2.74B $3.12B $2.82B
Deferred Tax Liabilities Non-Current $- $991.00M $1.39B $1.41B $1.55B
Other Non-Current Liabilities $6.00B $4.74B $5.74B $6.06B $6.18B
Total Non-Current Liabilities $20.55B $22.04B $26.07B $27.64B $25.72B
Other Liabilities $- $- $- $- $-
Total Liabilities $34.39B $37.53B $39.17B $39.55B $36.59B
Preferred Stock $- $- $- $- $-
Common Stock $24.87B $24.71B $24.47B $24.14B $23.85B
Retained Earnings $37.55B $35.26B $31.53B $27.63B $25.85B
Accumulated Other Comprehensive Income Loss $-7.84B $-8.05B $-8.37B $-8.95B $-8.46B
Other Total Stockholders Equity $-15.98B $-15.23B $-11.82B $-10.04B $-10.15B
Total Stockholders Equity $38.60B $36.69B $35.80B $32.78B $31.09B
Total Equity $38.83B $36.91B $36.02B $33.00B $31.30B
Total Liabilities and Stockholders Equity $73.21B $74.44B $75.20B $72.55B $67.89B
Minority Interest $224.00M $219.00M $222.00M $219.00M $213.00M
Total Liabilities and Total Equity $73.21B $74.44B $75.20B $72.55B $67.89B
Total Investments $1.18B $1.05B $1.27B $1.13B $1.16B
Total Debt $15.87B $17.72B $19.01B $19.65B $18.89B
Net Debt $8.98B $7.83B $9.21B $12.81B $15.03B


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Cash and Cash Equivalents $7.56B $6.99B $6.28B $6.90B $6.71B $7.83B $9.88B $9.88B $9.59B $8.94B $7.67B $9.80B $9.30B $8.66B $8.05B $6.84B $4.48B $4.76B $3.38B $3.86B
Short Term Investments $230.00M $232.00M $367.00M $383.00M $338.00M $320.00M $288.00M $288.00M $313.00M $353.00M $483.00M $450.00M $390.00M $286.00M $318.00M $310.00M $251.00M $274.00M $291.00M $280.00M
Cash and Short Term Investments $7.79B $7.22B $6.65B $7.28B $7.05B $8.15B $10.17B $10.17B $9.91B $9.29B $8.16B $10.25B $9.69B $8.94B $8.37B $7.15B $4.73B $5.04B $3.67B $4.14B
Net Receivables $9.20B $6.85B $6.61B $6.57B $6.50B $6.17B $6.02B $8.88B $6.41B $7.20B $7.18B $6.49B $6.41B $6.11B $6.10B $6.41B $5.65B $5.14B $5.29B $5.42B
Inventory $6.81B $6.81B $6.83B $6.57B $6.65B $6.87B $6.17B $6.17B $5.73B $5.90B $5.69B $5.16B $5.26B $5.44B $5.39B $5.01B $5.15B $5.20B $4.57B $4.32B
Other Current Assets $- $4.25B $4.42B $4.34B $2.47B $2.31B $2.15B $- $2.80B $2.57B $2.40B $2.35B $2.13B $2.13B $1.96B $1.87B $1.86B $1.84B $1.97B $1.79B
Total Current Assets $23.80B $23.12B $22.38B $22.67B $22.66B $23.50B $25.22B $25.22B $24.84B $24.96B $23.43B $24.24B $23.49B $22.63B $21.82B $20.44B $17.39B $17.22B $15.50B $15.67B
Property Plant Equipment Net $10.62B $10.23B $10.11B $11.28B $9.55B $9.45B $9.16B $9.16B $8.69B $8.82B $8.91B $8.96B $8.83B $8.82B $8.83B $9.03B $8.62B $8.34B $7.91B $8.04B
Goodwill $23.66B $23.31B $23.38B $23.68B $23.28B $23.26B $22.80B $22.80B $22.28B $22.74B $23.18B $23.23B $23.30B $23.48B $23.38B $23.74B $23.34B $23.08B $22.93B $23.20B
Intangible Assets $7.35B $7.83B $8.30B $8.81B $9.28B $9.83B $10.45B $10.45B $10.85B $11.59B $12.22B $12.74B $13.31B $13.68B $14.18B $14.78B $15.21B $15.80B $16.20B $17.02B
Goodwill and Intangible Assets $31.01B $31.14B $31.68B $32.49B $32.56B $33.09B $33.25B $33.25B $33.13B $34.34B $35.40B $35.97B $36.61B $37.17B $37.56B $38.53B $38.55B $38.88B $39.13B $40.22B
Long Term Investments $912.00M $877.00M $818.00M $799.00M $788.00M $799.00M $766.00M $766.00M $764.00M $734.00M $763.00M $816.00M $812.00M $805.00M $832.00M $821.00M $803.00M $776.00M $790.00M $883.00M
Tax Assets $- $7.65B $7.49B $- $6.53B $6.51B $6.03B $6.03B $5.37B $5.36B $5.50B $5.21B $4.05B $3.85B $3.74B $3.73B $3.68B $3.57B $3.39B $3.08B
Other Non-Current Assets $8.01B $- $- $5.97B $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Non-Current Assets $50.55B $49.90B $50.09B $50.54B $49.43B $49.85B $49.21B $49.21B $47.96B $49.25B $50.58B $50.96B $50.30B $50.64B $50.97B $52.11B $51.65B $51.57B $51.21B $52.22B
Other Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $74.36B $73.02B $72.47B $73.21B $72.09B $73.35B $74.44B $74.44B $72.80B $74.20B $74.01B $75.20B $73.80B $73.27B $72.78B $72.55B $69.04B $68.79B $66.71B $67.89B
Account Payables $4.03B $4.12B $4.18B $4.29B $3.96B $4.21B $4.17B $4.61B $4.13B $4.49B $4.76B $4.41B $4.02B $4.02B $4.07B $3.95B $3.19B $3.33B $3.18B $3.25B
Short Term Debt $2.15B $1.61B $2.01B $1.08B $1.05B $2.28B $2.29B $2.25B $1.12B $5.00M $4.00M $999.00M $951.00M $954.00M $955.00M $461.00M $214.00M $1.50B $1.47B $1.68B
Tax Payables $713.00M $601.00M $562.00M $492.00M $318.00M $273.00M $343.00M $343.00M $394.00M $355.00M $338.00M $306.00M $368.00M $242.00M $276.00M $362.00M $117.00M $165.00M $165.00M $226.00M
Deferred Revenue $- $601.00M $562.00M $1.45B $318.00M $273.00M $- $- $- $- $- $- $368.00M $242.00M $276.00M $362.00M $117.00M $165.00M $165.00M $226.00M
Other Current Liabilities $8.00B $7.42B $6.71B $7.97B $7.71B $7.58B $7.74B $8.29B $7.72B $7.54B $7.55B $7.39B $7.53B $7.40B $7.17B $7.14B $6.74B $5.96B $5.99B $5.70B
Total Current Liabilities $14.90B $13.76B $14.02B $13.84B $13.04B $14.35B $15.49B $15.49B $13.37B $12.39B $12.65B $13.11B $12.87B $12.61B $12.46B $11.91B $10.26B $10.96B $10.81B $10.86B
Long Term Debt $12.82B $13.14B $12.58B $14.55B $14.48B $14.56B $14.62B $15.46B $15.30B $16.75B $17.09B $18.25B $17.45B $17.55B $17.49B $19.43B $18.35B $18.18B $16.80B $17.42B
Deferred Revenue Non-Current $- $-6.56B $-6.83B $949.00M $-6.88B $-7.04B $-7.42B $- $-8.26B $-8.34B $- $- $- $- $- $- $- $-8.84B $-8.74B $-
Deferred Tax Liabilities Non-Current $- $6.56B $6.83B $1.22B $6.88B $7.04B $7.52B $991.00M $8.26B $8.34B $- $1.39B $- $- $- $1.41B $- $8.84B $8.74B $1.55B
Other Non-Current Liabilities $6.60B $6.56B $6.83B $4.78B $6.88B $7.04B $7.42B $5.59B $8.26B $8.34B $8.64B $5.74B $8.84B $9.08B $9.05B $6.06B $8.84B $8.84B $8.74B $6.18B
Total Non-Current Liabilities $19.43B $19.70B $19.40B $20.55B $21.35B $21.60B $22.04B $22.04B $23.55B $25.09B $25.73B $26.07B $26.29B $26.63B $26.54B $27.64B $27.19B $27.02B $25.54B $25.72B
Other Liabilities $- $- $- $- $- $- $-971.00M $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $34.33B $33.46B $33.42B $34.39B $34.40B $35.95B $36.56B $37.53B $36.92B $37.49B $38.38B $39.17B $39.16B $39.24B $39.00B $39.55B $37.45B $37.98B $36.35B $36.59B
Preferred Stock $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock $25.02B $24.86B $24.73B $24.87B $24.73B $24.61B $24.71B $24.71B $24.56B $24.43B $24.30B $24.47B $24.29B $24.15B $24.02B $24.14B $24.04B $23.89B $23.73B $23.85B
Retained Earnings $39.06B $38.35B $38.01B $37.55B $36.92B $36.35B $35.87B $35.26B $35.12B $34.49B $33.30B $31.53B $30.38B $29.05B $28.67B $27.63B $26.27B $25.67B $25.79B $25.85B
Accumulated Other Comprehensive Income Loss $-7.80B $-8.13B $-8.17B $-7.84B $-8.48B $-8.07B $-8.05B $-8.05B $-9.45B $-8.71B $-8.47B $-8.37B $-9.24B $-9.07B $-9.29B $-8.95B $-9.04B $-9.08B $-9.39B $-8.46B
Other Total Stockholders Equity $-16.48B $-15.76B $-15.76B $-15.98B $-15.69B $-15.72B $-15.31B $-15.23B $-14.55B $-13.72B $-13.73B $-11.82B $-11.00B $-10.34B $-9.85B $-10.04B $-9.87B $-9.90B $-9.91B $-10.15B
Total Stockholders Equity $39.80B $39.32B $38.81B $38.60B $37.48B $37.17B $74.22B $36.69B $35.67B $36.49B $35.40B $35.80B $34.42B $33.80B $33.56B $32.78B $31.39B $30.58B $30.22B $31.09B
Total Equity $40.03B $39.56B $39.04B $38.83B $37.69B $37.40B $74.44B $36.91B $35.88B $36.72B $35.63B $36.02B $34.64B $34.03B $33.79B $33.00B $31.59B $30.80B $30.43B $31.30B
Total Liabilities and Stockholders Equity $74.36B $73.02B $72.47B $73.21B $72.09B $73.35B $74.44B $74.44B $72.80B $74.20B $74.01B $75.20B $73.80B $73.27B $72.78B $72.55B $69.04B $68.78B $66.78B $67.89B
Minority Interest $232.00M $242.00M $233.00M $224.00M $213.00M $230.00M $222.00M $219.00M $209.00M $226.00M $230.00M $222.00M $216.00M $229.00M $226.00M $219.00M $209.00M $220.00M $209.00M $213.00M
Total Liabilities and Total Equity $74.36B $73.02B $72.47B $73.21B $72.09B $73.35B $74.44B $74.44B $72.80B $74.20B $74.01B $75.20B $73.80B $73.27B $72.78B $72.55B $69.04B $68.78B $66.78B $67.89B
Total Investments $1.14B $1.11B $1.19B $1.18B $1.13B $1.12B $1.05B $1.05B $1.08B $784.00M $1.25B $1.27B $1.20B $1.09B $1.15B $1.13B $1.05B $1.05B $1.08B $1.16B
Total Debt $14.98B $14.75B $14.59B $15.87B $15.53B $16.85B $16.77B $17.72B $16.41B $16.76B $17.09B $19.01B $18.40B $18.50B $18.44B $19.65B $18.56B $19.68B $18.27B $18.89B
Net Debt $7.42B $7.77B $8.30B $8.98B $8.82B $9.01B $6.89B $7.83B $6.82B $7.82B $9.41B $9.21B $9.10B $9.84B $10.39B $12.81B $14.08B $14.92B $14.89B $15.03B

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Net Income $5.72B $6.93B $7.07B $4.50B $3.69B
Depreciation and Amortization $3.24B $3.27B $3.54B $3.33B $3.01B
Deferred Income Tax $- $- $- $- $-
Stock Based Compensation $644.00M $685.00M $640.00M $546.00M $519.00M
Change in Working Capital $-2.48B $-1.52B $-771.00M $-892.00M $-1.33B
Accounts Receivables $-356.00M $-68.00M $-383.00M $-924.00M $-275.00M
Inventory $-232.00M $-1.41B $-456.00M $-493.00M $-593.00M
Accounts Payables $-760.00M $420.00M $1.29B $1.77B $220.00M
Other Working Capital $-1.13B $-458.00M $-1.22B $-1.24B $-683.00M
Other Non Cash Items $126.00M $215.00M $55.00M $425.00M $247.00M
Net Cash Provided by Operating Activities $7.26B $9.58B $10.53B $7.90B $6.14B
Investments in Property Plant and Equipment $-2.20B $-1.78B $-1.89B $-2.18B $-1.64B
Acquisitions Net $-837.00M $48.00M $-53.00M $16.00M $-122.00M
Purchases of Investments $-159.00M $-185.00M $-173.00M $-83.00M $-103.00M
Sales Maturities of Investments $43.00M $152.00M $77.00M $10.00M $21.00M
Other Investing Activities $22.00M $22.00M $26.00M $19.00M $27.00M
Net Cash Used for Investing Activities $-3.13B $-1.74B $-2.01B $-2.21B $-1.81B
Debt Repayment $-2.48B $-699.00M $-248.00M $-50.00M $-1.60B
Common Stock Issued $- $- $- $- $-
Common Stock Repurchased $-1.23B $-3.79B $-2.30B $-403.00M $-718.00M
Dividends Paid $-3.56B $-3.31B $-3.20B $-2.56B $-2.27B
Other Financing Activities $167.00M $167.00M $255.00M $234.00M $298.00M
Net Cash Used Provided by Financing Activities $-7.09B $-7.64B $-5.49B $-2.78B $-4.29B
Effect of Forex Changes on Cash $-23.00M $-122.00M $-70.00M $71.00M $-16.00M
Net Change in Cash $-2.99B $83.00M $2.96B $2.98B $16.00M
Cash at End of Period $6.90B $9.88B $9.80B $6.84B $3.86B
Cash at Beginning of Period $9.88B $9.80B $6.84B $3.86B $3.84B
Operating Cash Flow $7.26B $9.58B $10.53B $7.90B $6.14B
Capital Expenditure $-2.20B $-1.78B $-1.89B $-2.18B $-1.64B
Free Cash Flow $5.06B $7.80B $8.65B $5.72B $4.50B

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Net Income $1.64B $1.30B $1.22B $1.59B $1.44B $1.38B $1.32B $1.03B $1.44B $2.02B $2.45B $1.99B $2.10B $1.19B $1.79B $2.16B $1.23B $537.00M $564.00M $1.05B
Depreciation and Amortization $801.00M $805.00M $805.00M $813.00M $824.00M $800.00M $806.00M $807.00M $815.00M $822.00M $823.00M $883.00M $847.00M $874.00M $934.00M $866.00M $808.00M $825.00M $828.00M $756.00M
Deferred Income Tax $- $- $- $-1.38B $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Stock Based Compensation $117.00M $141.00M $304.00M $114.00M $117.00M $132.00M $281.00M $115.00M $123.00M $142.00M $305.00M $106.00M $114.00M $132.00M $288.00M $98.00M $100.00M $115.00M $233.00M $85.00M
Change in Working Capital $141.00M $-288.00M $-1.31B $391.00M $-321.00M $-444.00M $-186.00M $114.00M $336.00M $-664.00M $-1.30B $-106.00M $-323.00M $30.00M $-372.00M $289.00M $-321.00M $-319.00M $-541.00M $-244.00M
Accounts Receivables $- $-325.00M $-151.00M $68.00M $-461.00M $-196.00M $233.00M $341.00M $530.00M $-188.00M $-751.00M $-189.00M $-394.00M $35.00M $165.00M $-581.00M $-470.00M $231.00M $-104.00M $82.00M
Inventory $220.00M $-103.00M $-410.00M $295.00M $140.00M $-248.00M $-419.00M $-189.00M $-194.00M $-476.00M $-554.00M $15.00M $71.00M $-5.00M $-537.00M $345.00M $149.00M $-550.00M $-437.00M $137.00M
Accounts Payables $- $- $- $-1.34B $179.00M $660.00M $- $- $-71.00M $- $- $1.29B $- $- $-9.36B $1.77B $-7.13B $-6.26B $-4.69B $220.00M
Other Working Capital $-79.00M $140.00M $-748.00M $1.37B $-179.00M $-660.00M $186.00M $-38.00M $71.00M $92.00M $-205.00M $-1.22B $-37.00M $-97.00M $9.36B $-1.24B $7.13B $6.26B $4.69B $-683.00M
Other Non Cash Items $6.00M $2.18B $2.48B $1.51B $-179.00M $-660.00M $-1.08B $257.00M $71.00M $92.00M $-205.00M $195.00M $-37.00M $-97.00M $-6.00M $383.00M $247.00M $164.00M $-369.00M $770.00M
Net Cash Provided by Operating Activities $2.71B $1.96B $1.02B $3.04B $1.88B $1.20B $1.14B $2.33B $2.78B $2.41B $2.06B $3.07B $2.70B $2.13B $2.64B $3.80B $2.07B $1.32B $715.00M $2.42B
Investments in Property Plant and Equipment $- $-533.00M $-398.00M $-755.00M $-560.00M $-507.00M $-380.00M $-610.00M $-467.00M $-379.00M $-321.00M $-614.00M $-461.00M $-413.00M $-397.00M $-679.00M $-496.00M $-642.00M $-360.00M $-434.00M
Acquisitions Net $-1.00M $1.00M $- $-40.00M $-51.00M $-786.00M $- $- $- $48.00M $- $-134.00M $-86.00M $48.00M $-15.00M $-58.00M $- $16.00M $- $1.00M
Purchases of Investments $9.00M $28.00M $-28.00M $-114.00M $-38.00M $79.00M $-86.00M $- $-3.00M $41.00M $-41.00M $-173.00M $-27.00M $14.00M $-14.00M $-83.00M $- $- $-36.00M $-103.00M
Sales Maturities of Investments $-40.00M $49.00M $- $43.00M $38.00M $707.00M $- $- $- $- $- $77.00M $-81.00M $81.00M $- $10.00M $- $- $- $21.00M
Other Investing Activities $-562.00M $2.00M $1.00M $2.00M $-23.00M $-706.00M $4.00M $-22.00M $-14.00M $8.00M $2.00M $173.00M $-104.00M $101.00M $4.00M $79.00M $24.00M $7.00M $3.00M $26.00M
Net Cash Used for Investing Activities $-594.00M $-453.00M $-425.00M $-824.00M $-634.00M $-1.21B $-462.00M $-632.00M $-484.00M $-264.00M $-360.00M $-671.00M $-651.00M $-264.00M $-422.00M $-731.00M $-472.00M $-619.00M $-393.00M $-489.00M
Debt Repayment $43.00M $160.00M $-127.00M $-939.00M $-1.51B $12.00M $-42.00M $10.00M $24.00M $10.00M $-743.00M $-196.00M $-67.00M $-7.00M $22.00M $-1.00M $-1.36B $1.26B $50.00M $-1.13B
Common Stock Issued $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock Repurchased $-751.00M $-3.00M $-226.00M $-259.00M $-2.00M $-426.00M $-540.00M $-685.00M $-798.00M $-5.00M $-2.31B $-974.00M $-579.00M $-471.00M $-275.00M $-161.00M $-2.00M $-4.00M $-236.00M $-496.00M
Dividends Paid $-960.00M $-961.00M $-957.00M $-888.00M $-888.00M $-890.00M $-890.00M $-823.00M $-826.00M $-828.00M $-832.00M $-798.00M $-801.00M $-803.00M $-800.00M $-641.00M $-639.00M $-642.00M $-638.00M $-568.00M
Other Financing Activities $92.00M $13.00M $134.00M $34.00M $56.00M $15.00M $62.00M $41.00M $57.00M $10.00M $59.00M $82.00M $70.00M $17.00M $86.00M $16.00M $83.00M $46.00M $89.00M $7.00M
Net Cash Used Provided by Financing Activities $-1.58B $-791.00M $-1.18B $-2.05B $-2.34B $-1.29B $-1.41B $-1.46B $-1.54B $-813.00M $-3.82B $-1.89B $-1.38B $-1.26B $-967.00M $-787.00M $-1.92B $658.00M $-735.00M $-2.19B
Effect of Forex Changes on Cash $36.00M $-13.00M $-36.00M $25.00M $-29.00M $-27.00M $8.00M $51.00M $-96.00M $-71.00M $-6.00M $-13.00M $-29.00M $4.00M $-32.00M $78.00M $38.00M $25.00M $-70.00M $27.00M
Net Change in Cash $571.00M $703.00M $-612.00M $187.00M $-1.13B $-1.33B $-721.00M $288.00M $657.00M $1.26B $-2.12B $497.00M $644.00M $604.00M $1.22B $2.36B $-283.00M $1.39B $-483.00M $-231.00M
Cash at End of Period $7.56B $6.99B $6.28B $6.90B $6.71B $7.83B $9.16B $9.88B $9.59B $8.94B $7.67B $9.80B $9.30B $8.66B $8.05B $6.84B $4.48B $4.76B $3.38B $3.86B
Cash at Beginning of Period $6.99B $6.28B $6.90B $6.71B $7.83B $9.16B $9.88B $9.59B $8.94B $7.67B $9.80B $9.30B $8.66B $8.05B $6.84B $4.48B $4.76B $3.38B $3.86B $4.09B
Operating Cash Flow $2.71B $1.96B $1.02B $3.04B $1.88B $1.20B $1.14B $2.33B $2.78B $2.41B $2.06B $3.07B $2.70B $2.13B $2.64B $3.80B $2.07B $1.32B $715.00M $2.42B
Capital Expenditure $-556.00M $-533.00M $-398.00M $-755.00M $-560.00M $-507.00M $-380.00M $-610.00M $-467.00M $-379.00M $-321.00M $-614.00M $-461.00M $-413.00M $-397.00M $-679.00M $-496.00M $-642.00M $-360.00M $-434.00M
Free Cash Flow $2.15B $1.43B $627.00M $2.28B $1.32B $696.00M $763.00M $1.72B $2.31B $2.03B $1.74B $2.45B $2.24B $1.72B $2.24B $3.12B $1.57B $680.00M $355.00M $1.98B


Abbott Laboratories Stock Forecast

Analyst ratings, price targets, and earnings estimates for ABT.

ABT Analyst Ratings

Strong Buy

Buy
15
Hold
2
Sell
0

Based on 17 analysts in the past 3 months

ABT Stock 12 Month Forecast

$135.00

▲ (3.36% Upside)
Highest Price Target
$ (0.0%)
Average Price Target
$135.00 (3.4%)
Lowest Price Target
$ (0.0%)

Based on 1 analysts in the last 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $45.00B
Average $44.38B
Low $44.24B
20 analysts
Net Income Estimates
High $9.10B
Average $8.99B
Low $8.88B
20 analysts
EPS Estimates
High $5.21
Average $5.16
Low $5.08
17 analysts
Revenue Estimates
High $48.65B
Average $47.62B
Low $47.18B
20 analysts
Net Income Estimates
High $10.72B
Average $10.17B
Low $9.61B
20 analysts
EPS Estimates
High $6.13
Average $5.70
Low $5.49
16 analysts
Revenue Estimates
High $51.13B
Average $51.09B
Low $51.04B
17 analysts
Net Income Estimates
High $12.22B
Average $10.96B
Low $9.71B
17 analysts
EPS Estimates
High $6.99
Average $6.30
Low $5.55
8 analysts
Revenue Estimates
High $55.85B
Average $54.53B
Low $53.94B
8 analysts
Net Income Estimates
High $12.48B
Average $12.10B
Low $11.93B
8 analysts
EPS Estimates
High $7.14
Average $6.92
Low $6.82
6 analysts
Revenue Estimates
High $59.91B
Average $58.49B
Low $57.86B
13 analysts
Net Income Estimates
High $13.71B
Average $13.29B
Low $13.11B
13 analysts
EPS Estimates
High $7.84
Average $7.60
Low $7.49
5 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Jan 08, 2025 Lee Hambright Bernstein $135.00 $114.25 18.2%
Oct 17, 2024 Adam Maeder Piper Sandler $133.00 $117.82 12.9%
Oct 17, 2024 Lee Hambright Bernstein $138.00 $117.82 17.1%
Oct 16, 2024 Matthew Taylor Jefferies $125.00 $117.82 6.1%
Oct 16, 2024 Vijay Kumar Evercore ISI $128.00 $117.82 8.6%
Oct 16, 2024 Marie Thibault BTIG $139.00 $117.82 18.0%
Oct 08, 2024 Charles Minervino Susquehanna $120.00 $114.30 5.0%
Oct 08, 2024 Suraj Kalia Oppenheimer $130.00 $114.30 13.7%
Oct 08, 2024 Shagun Singh RBC Capital $130.00 $113.36 14.7%
Sep 19, 2024 Jonathan Atkin RBC Capital $345.00 $54.49 533.1%

Abbott Laboratories Dividends

Explore Abbott Laboratories's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

1.86%

Dividend Payout Ratio

62.14%

Dividend Paid & Capex Coverage Ratio

1.26x



Abbott Laboratories Dividend History

Dividend Adjusted Dividend Date Record Date Payment Date Declaration Date
$0.59 $0.59 January 15, 2025 January 15, 2025 February 14, 2025 December 13, 2024
$0.55 $0.55 October 15, 2024 October 15, 2024 November 15, 2024 September 19, 2024
$0.55 $0.55 July 15, 2024 July 15, 2024 August 15, 2024 June 14, 2024
$0.55 $0.55 April 12, 2024 April 15, 2024 May 15, 2024 February 16, 2024
$0.55 $0.55 January 11, 2024 January 12, 2024 February 15, 2024 December 15, 2023
$0.51 $0.51 October 12, 2023 October 13, 2023 November 15, 2023 September 21, 2023
$0.51 $0.51 July 13, 2023 July 14, 2023 August 15, 2023 June 09, 2023
$0.51 $0.51 April 13, 2023 April 14, 2023 May 15, 2023 February 17, 2023
$0.51 $0.51 January 12, 2023 January 13, 2023 February 15, 2023 December 09, 2022
$0.47 $0.47 October 13, 2022 October 14, 2022 November 15, 2022 September 15, 2022
$0.47 $0.47 July 14, 2022 July 15, 2022 August 15, 2022 June 10, 2022
$0.47 $0.47 April 13, 2022 April 15, 2022 May 16, 2022 February 18, 2022
$0.47 $0.47 January 13, 2022 January 14, 2022 February 15, 2022 December 10, 2021
$0.45 $0.45 October 14, 2021 October 15, 2021 November 15, 2021 September 15, 2021
$0.45 $0.45 July 14, 2021 July 15, 2021 August 16, 2021 June 11, 2021
$0.45 $0.45 April 14, 2021 April 15, 2021 May 17, 2021 February 19, 2021
$0.45 $0.45 January 14, 2021 January 15, 2021 February 16, 2021 December 11, 2020
$0.36 $0.36 October 14, 2020 October 15, 2020 November 16, 2020 September 17, 2020
$0.36 $0.36 July 14, 2020 July 15, 2020 August 17, 2020 June 12, 2020
$0.36 $0.36 April 14, 2020 April 15, 2020 May 15, 2020 February 21, 2020

Peers: Medical - Devices

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
ABBV Logo
AbbVie Inc.
ABBV
$340.83B $192.87 $2.42 $73.48 $94.54
LLY Logo
Eli Lilly and Company
LLY
$801.48B $844.27 $11.71 $65.93 $48.75
BMY Logo
Bristol-Myers Squibb Company
BMY
$109.38B $53.90 $-4.41 $-12.82 $7.02
JNJ Logo
Johnson & Johnson
JNJ
$375.95B $156.15 $5.84 $24.53 $27385.90
MDT Logo
Medtronic plc
MDT
$119.01B $92.81 $2.77 $28.80 $2.11

Related Metrics

Explore detailed financial metrics and analysis for ABT.

Ownership